Member Info for ChrisToffer

"he's not the messiah, he's a very naught boy!"

He actually didn't sell. He exercised options on the 15th October but the RNS doesn't state that he sold. Scinv just has a huge axe to grind.

They're his options to do what he likes with Scinv. At this current level the SP is up over 2000% since the start of the year so there won't be many who will begrudge him exercising those options.

FS Scinv, you were the one shouting about no peer review and claiming that RM was a crook because they hadn't published. You're still not happy! Says it all really.....

There ya go Doc!:D

Better to tell the world that P3 has started rather than it is going to start. I doubt that webinar next Wednesday is for the peer review.

It was worth up to 240 million in 2014!

"With a vaccine you don't need therapeutics. " The idiotic comment of the year award goes to *drum roll* DACORUM!

There was no 2nd RNS. It's LSE playing up (as usual).

Shan, all new shares are now issued. See 2nd Nov RNS

I actually got caught with my pants down trying to trade 7% of my holding but would love for this to shoot up! Just hope i don't lose too many from my original holding!

Antofelli, "This might carry additional advantages of treating COVID-19 when it occurs alongside infection by another respiratory virus such as influenza or Respiratory Syncytial Virus that may well be encountered in the winter months."
SNG001 has yet to be proven in the treatment of covid in patients who have Flu etc. during the winter months therefore TW is obliged to say that. There are no treatments in place for the doubly whammy of covid sufferers and seasonal viruses.

1.75 was the open offer price where they raised 87 million only a few weeks back. Make what ya want from that!

Hahaha i'm tied to the bloody mast Nolupus!

Benm, we're all frustrated with this weeks events but SNG may well complete a P2 and P3 trial within a 12 month period. You know how long that can normally take?

Hi Nolupus, What's your take on the current situation?

How can we expect vaccine papers in the lancet when we haven't even seen 1 set of topline data?

hmm, just in time for the webinar on the 18th

You could be right Joey and if the other vaccine candidates come in with successful results we may see a lot more volatility. How that affects SNG001's licencing value is hard to predict but it'll still be worth a lot more than the current market cap. I think it'll still be a lot more than £2 a share

Hi Andy, successful vaccines were clearly not priced into the market and the general interpretation that this one is a golden bullet (mostly by PI's) contributed to the huge drop. This is explained by the indiscriminate way the drop (and rise) affected a whole host of shares. Even NCYT got hit and they are and will continue to sell PCR tests for a long time yet. Future vaccine readouts may have a similar effect but i suspect it will be a lot more subdued.

SNG, like all other shares affected, should be assessed on its own merits. Fully funded for P3 trials for a broad spectrum anti viral that may well treat all future viruses as well as COPD et al. The value of an effective drug in p3 trials is way north of 190 million, let alone one that has a chance of completing the P3 within a few months.